Publications (96) MARIA VARELA CALVO publications

filter_list

2026

  1. Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

    Alimentary Pharmacology and Therapeutics, Vol. 63, Núm. 7, pp. 955-966

  2. Evidence-based guidelines on the use of prebiotics and probiotics in digestive diseases

    Medicina Clinica, Vol. 166, Núm. 2

  3. Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy

    OncoImmunology, Vol. 15, Núm. 1

  4. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)

    Future Oncology, Vol. 22, Núm. 12, pp. 1359-1372

2025

  1. Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy

    Liver International, Vol. 45, Núm. 9

  2. Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

    European Journal of Cancer, Vol. 221

  3. Corrigendum to” Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes,” [Eur J Cancer 2025 May 15:221:115404.] (European Journal of Cancer (2025) 221, (S0959804925001856), (10.1016/j.ejca.2025.115404))

    European Journal of Cancer

  4. Demographic and survival characteristics of untreated hepatocellular carcinoma patients: insights into the natural history and prognostic determinants

    Revista espanola de enfermedades digestivas, Vol. 117, Núm. 7, pp. 366-373

  5. Evolving epidemiology of HCC in Spain

    JHEP Reports, Vol. 7, Núm. 5

  6. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

    Journal of Hepatology, Vol. 83, Núm. 4, pp. 899-908

  7. Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial

    Journal of Patient-Reported Outcomes, Vol. 9, Núm. 1

  8. Hepatocellular carcinomas: Key contributions of the radiologist to the patient care team, with special focus on systemic treatment with immunotherapy

    Radiologia

  9. Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”

    JHEP Reports

  10. Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers

    ESMO Open, Vol. 10, Núm. 8

  11. The role of immigration in chronic hepatitis B and C in Asturias - Origin and characteristics of the patients. An observational, cross-sectional study

    Revista espanola de enfermedades digestivas, Vol. 117, Núm. 12, pp. 745-751

2023

  1. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

    Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516

  2. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 754-763

  3. Prevalence and pattern of alcohol consumption in patients with hepatocellular carcinoma

    Medicina Clinica, Vol. 161, Núm. 2, pp. 49-53

2022

  1. Low applicability of the ''Six-and-twelve score" in hepatocellular carcinoma treated with Drug-Eluting Beads Transarterial Chemoembolization

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 1, pp. 28-34

  2. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11